{"id":"propyphenazone","rwe":[{"pmid":"39568060","year":"2024","title":"Simultaneously quantifying a novel five-component anti- migraine formulation containing ergotamine, propyphenazone, caffeine, camylofin, and mecloxamine using UV spectrophotometry and chemometric models.","finding":"","journal":"BMC chemistry","studyType":"Clinical Study"},{"pmid":"39454511","year":"2024","title":"Proof-of-concept for removing micropollutants through a combination of sub-atmospheric-pressure non-thermal plasma and hydrodynamic (super)cavitation.","finding":"","journal":"Ultrasonics sonochemistry","studyType":"Clinical Study"},{"pmid":"39128353","year":"2024","title":"Microalgal-based carbon encapsulated iron nanoparticles for the removal of pharmaceutical compounds from wastewater.","finding":"","journal":"Journal of environmental management","studyType":"Clinical Study"},{"pmid":"38554875","year":"2024","title":"Application of non-lethal bioSPME-LC-MS/MS for the detection of human pharmaceuticals in soft corals: A survey at the North Nilandhe atoll (Maldives).","finding":"","journal":"Chemosphere","studyType":"Clinical Study"},{"pmid":"37865249","year":"2024","title":"Removal of pharmaceutical compounds from the liquid phase of anaerobic sludge in a pilot-scale high-rate algae-bacteria pond.","finding":"","journal":"The Science of the total environment","studyType":"Clinical Study"}],"tags":[{"label":"propyphenazone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Transient receptor potential cation channel subfamily A member 1","category":"target"},{"label":"TRPA1","category":"gene"},{"label":"N02BB04","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PROPYPHENAZONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:35:59.887234+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:36:16.364166+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:36:06.823797+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PROPYPHENAZONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:36:07.650187+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL28318/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:36:08.127472+00:00"}},"allNames":"yoshipyrin","offLabel":[],"synonyms":["yoshipyrin","propyphenazone","isopropchin","isopropylantipyrin","isopropylantipyrine","isopropylphenazone","isopropyrine","propyfenazone","propifenazone"],"timeline":[],"aiSummary":"Propyphenazone (Yoshipyrin) is a marketed analgesic that blocks the transient receptor potential cation channel subfamily A member 1, positioning it as a targeted pain management solution. Its key competitive advantage lies in its unique mechanism of action, distinguishing it from same-class competitors such as metamizole. The primary risk to Yoshipyrin's market position is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.","approvals":[],"brandName":"Yoshipyrin","ecosystem":[],"mechanism":{"target":"Transient receptor potential cation channel subfamily A member 1","targets":[{"gene":"TRPA1","source":"DrugCentral","target":"Transient receptor potential cation channel subfamily A member 1","protein":"Transient receptor potential cation channel subfamily A member 1"}],"modality":"Small Molecule","drugClass":"propyphenazone","explanation":"","oneSentence":"","technicalDetail":"Yoshipyrin acts as a TRPA1 antagonist, inhibiting the activation of the channel and subsequent pain signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2309","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PROPYPHENAZONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:27:19.176939","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:36:16.364785+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"metamizole","drugSlug":"metamizole","fdaApproval":"","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"propyphenazone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"metamizole","brandName":"metamizole","genericName":"metamizole","approvalYear":"","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"GEWORIN"},{"form":"TABLET","route":"ORAL","productName":"GEWORIN"}]},"crossReferences":{"MMSL":"d06973","NDDF":"004365","UNII":"OED8FV75PY","CHEBI":"CHEBI:135538","INN_ID":"2848","RXNORM":"34710","UMLSCUI":"C0072245","chemblId":"CHEMBL28318","ChEMBL_ID":"CHEMBL28318","KEGG_DRUG":"D01380","DRUGBANK_ID":"DB13524","PUBCHEM_CID":"3778","SNOMEDCT_US":"699188007","MESH_SUPPLEMENTAL_RECORD_UI":"C009077"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":179,"therapeuticAreas":["Pain"],"atcClassification":{"source":"DrugCentral","atcCode":"N02BB04","allCodes":["N02BB04","N02BB54","N02BB74"]},"biosimilarFilings":[],"recentPublications":[{"date":"2024 Nov 20","pmid":"39568060","title":"Simultaneously quantifying a novel five-component anti- migraine formulation containing ergotamine, propyphenazone, caffeine, camylofin, and mecloxamine using UV spectrophotometry and chemometric models.","journal":"BMC chemistry"},{"date":"2024 Dec","pmid":"39454511","title":"Proof-of-concept for removing micropollutants through a combination of sub-atmospheric-pressure non-thermal plasma and hydrodynamic (super)cavitation.","journal":"Ultrasonics sonochemistry"},{"date":"2024 Sep","pmid":"39128353","title":"Microalgal-based carbon encapsulated iron nanoparticles for the removal of pharmaceutical compounds from wastewater.","journal":"Journal of environmental management"},{"date":"2024 May","pmid":"38554875","title":"Application of non-lethal bioSPME-LC-MS/MS for the detection of human pharmaceuticals in soft corals: A survey at the North Nilandhe atoll (Maldives).","journal":"Chemosphere"},{"date":"2024 Jan 15","pmid":"37865249","title":"Removal of pharmaceutical compounds from the liquid phase of anaerobic sludge in a pilot-scale high-rate algae-bacteria pond.","journal":"The Science of the total environment"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:36:16.364785+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":false,"score":0}}